HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
August 24, 2021 07:32 ET | HCW Biologics, Inc
Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
August 17, 2021 07:32 ET | HCW Biologics, Inc
TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells MIRAMAR, Fla., Aug. 17, 2021 (GLOBE...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
August 13, 2021 07:10 ET | HCW Biologics, Inc
MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel...